5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front
'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis
Andrew Fein Recent News
Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar
Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend
What Analysts Have To Say About Insmed Following Arikayce Approval
H.C. Wainwright: Acadia Is More Than A One-Trick Pony
Analyst Says Axovant's Bull Case Is Effectively Over
Concert Pharma Shares Rally Over $15 Level Following New Buy Rating, $20 Price Target
Rigorous Trial Design, Nice Risk/Reward Keep Analyst Anxious For Avoxant's Phase 3 MINDSET Data
Looking For Leftover Value in Nivalis Following Drug Trial Miss
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
Vertex Pharmaceuticals Relapses To A Neutral Rating At H.C. Wainwright
TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track
'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says
H.C. Wainwright Downgrades United Therapeutics To Neutral
H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare
Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
Analyst Concerns On Vertex's Approved Drug
UPDATE: H.C. Wainwright Initiates Coverage on PharmAthene